Korean Drug Co. Ltd (014570) — Cash Flow-to-Debt Ratio
Korean Drug Co. Ltd (014570) has a Cash Flow-to-Debt Ratio of 0.09x as of June 2026, meaning its operating cash flow of ₩1.90 Billion could theoretically repay 0% of its total liabilities (₩20.08 Billion) in one year. See Korean Drug Co. Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Korean Drug Co. Ltd Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Korean Drug Co. Ltd across 12 annual periods. For the full cash flow conversion analysis, see how efficiently does Korean Drug Co. Ltd generate cash.
Annual Cash Flow-to-Debt Ratio for Korean Drug Co. Ltd (2014–2025)
Year-by-year debt coverage analysis for Korean Drug Co. Ltd. Check Korean Drug Co. Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.17x | ₩13.11 Billion | ₩11.25 Billion | ▲ +158.1% |
| 2024 | 0.45x | ₩4.87 Billion | ₩10.78 Billion | ▲ +385.1% |
| 2023 | -0.16x | ₩-2.00 Billion | ₩12.62 Billion | ▼ -126.3% |
| 2022 | 0.60x | ₩5.91 Billion | ₩9.80 Billion | ▼ -18.3% |
| 2021 | 0.74x | ₩8.81 Billion | ₩11.92 Billion | ▼ -25.3% |
| 2020 | 0.99x | ₩12.33 Billion | ₩12.47 Billion | ▲ +71.9% |
| 2019 | 0.57x | ₩6.21 Billion | ₩10.80 Billion | ▲ +0.9% |
| 2018 | 0.57x | ₩5.79 Billion | ₩10.16 Billion | ▲ +1150.7% |
| 2017 | 0.05x | ₩447.20 Million | ₩9.82 Billion | ▼ -88.8% |
| 2016 | 0.41x | ₩3.96 Billion | ₩9.75 Billion | ▼ -36.9% |
| 2015 | 0.64x | ₩6.13 Billion | ₩9.52 Billion | ▲ +93.2% |
| 2014 | 0.33x | ₩4.46 Billion | ₩13.38 Billion | — |